Results of Operations and Financial Condition. On July 30, 2026, Alignment Healthcare, Inc. issued a press release announcing its financial results for its second quarter ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The information contained in this Current Report on Form 8-K and in the accompanying exhibit are “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…

Results of Operations and Financial Condition. On April 30, 2026, Alignment Healthcare, Inc. issued a press release announcing its financial results for its first quarter ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The information contained in this Current Report on Form 8-K and in the accompanying exhibit are “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act o…

Entry into a Material Definitive Agreement. On March 2, 2026, Alignment Healthcare, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC (the “Underwriter”) and the selling stockholder listed on Schedule II thereto (the “Selling Stockholder”) with respect to an underwritten offering by the Selling Stockholder of 13,167,733 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”),…

Results of Operations and Financial Condition. On February 26, 2026, Alignment Healthcare, Inc. issued a press release announcing its financial results for its fourth quarter and full year ended Dec. 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The information contained in this Current Report on Form 8-K and in the accompanying exhibit are “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securiti…

Regulation FD Disclosure. Members of the Company’s senior management team are scheduled to meet with investors and analysts at an industry conference and various other meetings on January 12-15, 2026. During the conference and meetings, the Company intends to address aspects of its prospects and performance as described below. The date and time of presentations to investors are available via the Investor Relations calendar of events and presentations on the Company's website at www.alignmenth…

Results of Operations and Financial Condition. On October 30, 2025, Alignment Healthcare, Inc. issued a press release announcing its financial results for its third quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The information contained in this Current Report on Form 8-K and in the accompanying exhibit are “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange…

Regulation FD Disclosure. Senior leaders from Alignment Healthcare, Inc. (the "Company") are meeting with investors and analysts between September 9, 2025 and September 10, 2025, during which the Company intends to discuss its strategy, market position and recent results. The Company will also discuss preliminary Centers for Medicare & Medicaid Services (CMS) Medicare Advantage Star ratings for rating year 2026 / payment year 2027. While the related data is still under evaluation, based on a…

Results of Operations and Financial Condition. On July 30, 2025, Alignment Healthcare, Inc. issued a press release announcing its financial results for its second quarter ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The information contained in this Current Report on Form 8-K and in the accompanying exhibit are “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…

Results of Operations and Financial Condition. On May 1, 2025, Alignment Healthcare, Inc. issued a press release announcing its financial results for its first quarter ended March 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The information contained in this Current Report on Form 8-K and in the accompanying exhibit are “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1…

Chief Experience Officer — Hakan Kardes: The Chief Experience Officer resigned to pursue other opportunities with a transition period, representing a genuine executive departure but not a sudden shock event.

Other Information. As previously disclosed, on April 30, 2024, Alignment Healthcare, Inc. (the "Company") entered into an amended and restated stockholders agreement with funds managed by General Atlantic and Warburg Pincus LLC, which, among other things, had the effect of rendering moot the stockholder lawsuit captioned Maglione v. Konowiecki, et. al. , C.A. No. 2023-0691-JTL (Del. Ch.) (the Action”). As previously disclosed, on May 24, 2024, the Court of Chancery of the State of Delaware en…

Results of Operations and Financial Condition. On February 27, 2025, Alignment Healthcare, Inc. issued a press release announcing its financial results for its fourth quarter and full year ended December 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The information contained in this Current Report on Form 8-K and in the accompanying exhibit are “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Secu…

President — Dawn Maroney: The filing announces the internal promotion of Dawn Maroney to President, which is a standard succession or expansion of duties rather than a departure.

Regulation FD Disclosure. Members of the Company’s senior management team are scheduled to meet with investors and analysts at an industry conference and various other meetings on January 13-16, 2025. During the conference and meetings, the Company intends to address aspects of its prospects and performance as described below. The date and time of presentations to investors are available via the Investor Relations calendar of events and presentations on the Company's website at www.alignmenth…

of this Current Report on Form 8-K, and intends to use the remaining proceeds for general corporate purposes. The foregoing descriptions of the Indenture and the Notes do not purport to be complete and are qualified in their entirety by reference to the Indenture (including the form of Note included therein), a copy of which is filed as Exhibit 4.1 to this Current Report on Form 8-K and incorporated herein by reference. This Current Report on Form 8-K does not constitute an offer to sell, nor…

Unregistered Sales of Equity Securities. The information set forth in

of this Current Report on Form 8-K is incorporated herein by reference. The Notes were issued pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act. The Company is relying on this exemption from registration in part based on representations made by the investors in the Notes in the subscription agreements pursuant to which the Notes were sold, including representations that each such investor is an institutional “accredited investor” as defined in Rule…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Unregistered Sales of Equity Securities. The information set forth in

Entry into a Material Definitive Agreement. Subscription Agreements On November 14, 2024, Alignment Healthcare, Inc. (the “Company”) entered into privately negotiated subscription agreements (the “Subscription Agreements”) with certain investors (the “Investors”), pursuant to which the Company will issue $330 million aggregate principal amount of 4.25% Convertible Senior Notes due 2029 (the “Notes”). The Notes will be issued in reliance on the exemption from registration provided by Section 4…

and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information and exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. Cautionary Note Regarding Forward-Looking Statements This…

Results of Operations and Financial Condition. On October 29, 2024, Alignment Healthcare, Inc. issued a press release announcing its financial results for its third quarter ended September 30, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The information contained in this Current Report on Form 8-K and in the accompanying exhibit are “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange…

Director — Jeffrey Margolis: Two directors resigned simultaneously, reducing the board size, but the filing notes no disagreement and one resigned director entered a consulting agreement, suggesting an orderly transition rather than a crisis.

Results of Operations and Financial Condition. On August 1, 2024, Alignment Healthcare, Inc. issued a press release announcing its financial results for its second quarter ended June 30, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The information contained in this Current Report on Form 8-K and in the accompanying exhibit are “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act o…

of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on September 6, 2022 and are incorporated herein by reference. The foregoing discussion of the terms of the Loan Agreement is not complete and is subject to, and qualified in its entirety by reference to, the Loan Agreement filed as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed with the SEC on November 3, 2022. SIGNATURE Pursuant to the requirements of the Securities Excha…